Main clinical characteristics of 32 patients with multiple myeloma
Patient no. . | Sex . | Age, y . | HC . | LC . | Disease status . | Stage . | Lytic bone lesions . |
---|---|---|---|---|---|---|---|
1 | F | 58 | λ | D | IIIA | + | |
2 | F | 50 | K | D | IIIA | + | |
3 | F | 51 | G | λ | D | IA | + |
4 | M | 70 | A | λ | D | IIIA | + |
5 | F | 82 | λ | D | IIIB | + | |
6 | M | 82 | G | λ | D | IIIA | + |
7 | F | 65 | λ | D | IIIA | + | |
8 | F | 53 | G | K | D | IIIA | + |
9 | M | 64 | A | K | PR | IIA | + |
10 | F | 72 | G | K | PR | IA | + |
11 | M | 74 | G | K | PR | IIIA | + |
12 | F | 62 | A | λ | PR | IIIB | + |
13 | F | 65 | G | K | OR | IIIA | + |
14 | F | 58 | A | λ | Relapse | IIIA | + |
15 | F | 74 | G | K | Relapse | IIIA | + |
16 | F | 62 | K | NR-PD | IIIB | + | |
17 | M | 76 | G | K | NR-PD | IIIA | + |
18 | M | 74 | G | K | NR-PD | IIIA | + |
19 | M | 69 | G | λ | NR-SD | IIIA | + |
20 | M | 73 | G | K | D | IA | - |
21 | F | 74 | G | K | Relapse | IIIA | - |
22 | F | 55 | G | K | D | IIA | - |
23 | M | 55 | G | K | Relapse | IIA | - |
24 | M | 59 | A | λ | D | IIA | - |
25 | M | 71 | A | K | D | IIA | - |
26 | M | 63 | G | K | Relapse | IIA | - |
27 | M | 57 | A | K | Relapse | IIA | - |
28 | F | 66 | G | λ | D | IIIA | + |
29 | M | 62 | G | K | Relapse | IIIA | + |
30 | M | 73 | G | λ | D | IIIA | + |
31 | F | 75 | G | K | D | IIIA | + |
32 | F | 67 | G | K | D | IIIA | + |
Patient no. . | Sex . | Age, y . | HC . | LC . | Disease status . | Stage . | Lytic bone lesions . |
---|---|---|---|---|---|---|---|
1 | F | 58 | λ | D | IIIA | + | |
2 | F | 50 | K | D | IIIA | + | |
3 | F | 51 | G | λ | D | IA | + |
4 | M | 70 | A | λ | D | IIIA | + |
5 | F | 82 | λ | D | IIIB | + | |
6 | M | 82 | G | λ | D | IIIA | + |
7 | F | 65 | λ | D | IIIA | + | |
8 | F | 53 | G | K | D | IIIA | + |
9 | M | 64 | A | K | PR | IIA | + |
10 | F | 72 | G | K | PR | IA | + |
11 | M | 74 | G | K | PR | IIIA | + |
12 | F | 62 | A | λ | PR | IIIB | + |
13 | F | 65 | G | K | OR | IIIA | + |
14 | F | 58 | A | λ | Relapse | IIIA | + |
15 | F | 74 | G | K | Relapse | IIIA | + |
16 | F | 62 | K | NR-PD | IIIB | + | |
17 | M | 76 | G | K | NR-PD | IIIA | + |
18 | M | 74 | G | K | NR-PD | IIIA | + |
19 | M | 69 | G | λ | NR-SD | IIIA | + |
20 | M | 73 | G | K | D | IA | - |
21 | F | 74 | G | K | Relapse | IIIA | - |
22 | F | 55 | G | K | D | IIA | - |
23 | M | 55 | G | K | Relapse | IIA | - |
24 | M | 59 | A | λ | D | IIA | - |
25 | M | 71 | A | K | D | IIA | - |
26 | M | 63 | G | K | Relapse | IIA | - |
27 | M | 57 | A | K | Relapse | IIA | - |
28 | F | 66 | G | λ | D | IIIA | + |
29 | M | 62 | G | K | Relapse | IIIA | + |
30 | M | 73 | G | λ | D | IIIA | + |
31 | F | 75 | G | K | D | IIIA | + |
32 | F | 67 | G | K | D | IIIA | + |
HC indicates heavy chain; LC, light chain; D, at diagnosis; PR, partial remission; OR, objective response; NR, no response; PD, progressive disease; SD, stable disease; + presence of lytic bone lesions; and -, absence of lytic bone lesions.